Cargando…
A Case Report of Clonazepam Dependence: Utilization of Therapeutic Drug Monitoring During Withdrawal Period
Clonazepam is long-acting benzodiazepine agonist used in short-acting benzodiazepine withdrawal; however, recent observations suggest the existence of its abuse. We demonstrate a 40-year-old man with a 20-year history of psychiatric care with recently benzodiazepine dependence (daily intake of ∼60 m...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782857/ https://www.ncbi.nlm.nih.gov/pubmed/26945373 http://dx.doi.org/10.1097/MD.0000000000002881 |
_version_ | 1782420025928318976 |
---|---|
author | Kacirova, Ivana Grundmann, Milan Silhan, Petr Brozmanova, Hana |
author_facet | Kacirova, Ivana Grundmann, Milan Silhan, Petr Brozmanova, Hana |
author_sort | Kacirova, Ivana |
collection | PubMed |
description | Clonazepam is long-acting benzodiazepine agonist used in short-acting benzodiazepine withdrawal; however, recent observations suggest the existence of its abuse. We demonstrate a 40-year-old man with a 20-year history of psychiatric care with recently benzodiazepine dependence (daily intake of ∼60 mg of clonazepam and 10 mg of alprazolam). High serum levels of both drugs were analyzed 3 weeks before admission to hospitalization (clonazepam 543.9 ng/mL, alprazolam 110 ng/mL) and at the time of admission (clonazepam 286.2 ng/mL, alprazolam 140 ng/mL) without any signs of benzodiazepine intoxication. Gradual withdrawal of clonazepam with monitoring of its serum levels and increase of gabapentin dose were used to minimize physical signs and symptoms of clonazepam withdrawal. Alprazolam was discontinued promptly. Clinical consequences of the treatment were controllable tension, intermittent headache, and rarely insomia. It is the first case report showing utilization of therapeutic drug monitoring during withdrawal period in the patient with extreme toleration to severe benzodiazepine dependence. |
format | Online Article Text |
id | pubmed-4782857 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-47828572016-03-24 A Case Report of Clonazepam Dependence: Utilization of Therapeutic Drug Monitoring During Withdrawal Period Kacirova, Ivana Grundmann, Milan Silhan, Petr Brozmanova, Hana Medicine (Baltimore) 5000 Clonazepam is long-acting benzodiazepine agonist used in short-acting benzodiazepine withdrawal; however, recent observations suggest the existence of its abuse. We demonstrate a 40-year-old man with a 20-year history of psychiatric care with recently benzodiazepine dependence (daily intake of ∼60 mg of clonazepam and 10 mg of alprazolam). High serum levels of both drugs were analyzed 3 weeks before admission to hospitalization (clonazepam 543.9 ng/mL, alprazolam 110 ng/mL) and at the time of admission (clonazepam 286.2 ng/mL, alprazolam 140 ng/mL) without any signs of benzodiazepine intoxication. Gradual withdrawal of clonazepam with monitoring of its serum levels and increase of gabapentin dose were used to minimize physical signs and symptoms of clonazepam withdrawal. Alprazolam was discontinued promptly. Clinical consequences of the treatment were controllable tension, intermittent headache, and rarely insomia. It is the first case report showing utilization of therapeutic drug monitoring during withdrawal period in the patient with extreme toleration to severe benzodiazepine dependence. Wolters Kluwer Health 2016-03-07 /pmc/articles/PMC4782857/ /pubmed/26945373 http://dx.doi.org/10.1097/MD.0000000000002881 Text en Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 |
spellingShingle | 5000 Kacirova, Ivana Grundmann, Milan Silhan, Petr Brozmanova, Hana A Case Report of Clonazepam Dependence: Utilization of Therapeutic Drug Monitoring During Withdrawal Period |
title | A Case Report of Clonazepam Dependence: Utilization of Therapeutic Drug Monitoring During Withdrawal Period |
title_full | A Case Report of Clonazepam Dependence: Utilization of Therapeutic Drug Monitoring During Withdrawal Period |
title_fullStr | A Case Report of Clonazepam Dependence: Utilization of Therapeutic Drug Monitoring During Withdrawal Period |
title_full_unstemmed | A Case Report of Clonazepam Dependence: Utilization of Therapeutic Drug Monitoring During Withdrawal Period |
title_short | A Case Report of Clonazepam Dependence: Utilization of Therapeutic Drug Monitoring During Withdrawal Period |
title_sort | case report of clonazepam dependence: utilization of therapeutic drug monitoring during withdrawal period |
topic | 5000 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782857/ https://www.ncbi.nlm.nih.gov/pubmed/26945373 http://dx.doi.org/10.1097/MD.0000000000002881 |
work_keys_str_mv | AT kacirovaivana acasereportofclonazepamdependenceutilizationoftherapeuticdrugmonitoringduringwithdrawalperiod AT grundmannmilan acasereportofclonazepamdependenceutilizationoftherapeuticdrugmonitoringduringwithdrawalperiod AT silhanpetr acasereportofclonazepamdependenceutilizationoftherapeuticdrugmonitoringduringwithdrawalperiod AT brozmanovahana acasereportofclonazepamdependenceutilizationoftherapeuticdrugmonitoringduringwithdrawalperiod AT kacirovaivana casereportofclonazepamdependenceutilizationoftherapeuticdrugmonitoringduringwithdrawalperiod AT grundmannmilan casereportofclonazepamdependenceutilizationoftherapeuticdrugmonitoringduringwithdrawalperiod AT silhanpetr casereportofclonazepamdependenceutilizationoftherapeuticdrugmonitoringduringwithdrawalperiod AT brozmanovahana casereportofclonazepamdependenceutilizationoftherapeuticdrugmonitoringduringwithdrawalperiod |